Vaccination against SARS-CoV-2 / COVID-19: Update and perspectives of vaccination in Colombia.
Article Sidebar
Main Article Content
Abstract
Background: The severe acute respiratory syndrome virus type-2 (SARS-CoV-2) is a type of
coronavirus that causes the coronavirus disease 2019 (COVID-19), responsible for the current
global public health crisis. Objective: To develop a review of the SARS-CoV-2 vaccination and
its role as a way out of the health crisis and to solve the economic and social burden that this
pandemic has generated. Through this review, the different platforms available in vaccination
will be evaluated and the challenges that Colombia faces in the mass vaccination process.
Conclusions: Thanks to the multinational effort, there are effective vaccines in less than one
year after the start of the pandemic. Vaccination options are comprehensive, and the medical
community must be adequately informed about its risks and benefits to contribute to the
mass vaccination process in the country.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
Ruiz Ponce de León I, Urbano Arcos JF, Oliveros OA, Mejía Rivera LF, Rojas Hernández JP. SARS-CoV-2 en pediatría. Historia de una pandemia desde China hasta Colombia. Interdiscip J Epidemiol Public Health 2020;3(1). https://revistas.unilibre.edu.co/index.php/iJEPH/article/view/6203 (Fecha de consulta: 20 de marzo, 2021).
Speil C, Rzepka R. Vaccines and Vaccine Adjuvants as Biological Response Modifiers. Infect Dis Clin North Am 2011;25(4):755-72.
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021;21(2):e26-35.
Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020;19(10):667-8.
Invima autoriza uso de emergencia de vacuna Pfizer en Colombia. Boletín de Prensa No 011. 5 de enero de 2021. https://www.minsalud.gov.co/Paginas/Invima-autoriza-uso-de-emergencia-de-vacuna-Pfizer-en-Colombia-.aspx (Fecha de consulta: 24 de febrero, 2021).
Invima otorgó visto bueno para la importación de la vacuna CoronaVac desarrollada por la farmacéutica Sinovac Life Sciences Co. Ltd. https://www.invima.gov.co/web/guest/invima-otorgo-visto-bueno-para-la-importacion-de-la-vacuna-coronavac-desarrollada-por-la-farmaceutica-sinovac-life-sciences-co-ltd?redirect=%2Fnoticias (Fecha de consulta: 24 de febrero, 2021).
Invima otorga Autorización de Uso de Emergencia – ASUE, para vacuna desarrollada por la farmacéutica AstraZeneca. https://www.invima.gov.co/invima-otorga-autorizacion-de-uso-de-emergencia-asue-para-vacuna-desarrollada-por-la-farmaceutica-astrazeneca (Fecha de consulta: 24 de febrero, 2021).
Invima aprobó la vacuna de Janssen contra la covid-19. https://www.semana.com/nacion/articulo/vacuna-contra-la-covid-19-de-janssen-esta-cerca-de-ser-autorizada-por-invima-para-su-ingreso-a-colombia/202108/ (Fecha de consulta: 2 de abril, 2021).
Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol 2020;50:101422.
Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D. The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics 2021;11(4):1690-702.
On behalf of the COVID-19 Commission of Accademia Nazionale dei Lincei, Rome, Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 2021;28(2):626-39.
Reina J. El SARS-CoV-2, una nueva zoonosis pandémica que amenaza al mundo. Vacunas 2020;21(1):17-22.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov 2018;17(4):261-79.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403-16.
Belete TM. Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease. Infect Drug Resist 2021;14:151-61.
Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. Patterns of COVID-19 pandemic dynamics following deployment of a broad national immunization program. http://medrxiv.org/lookup/doi/10.1101/2021.02.08.21251325 (Fecha de consulta: 20 de marzo, 2021)
Balakrishnan VS. The arrival of Sputnik V. Lancet Infect Dis 2020;20(10):1128.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet 2020;396(10255):887-97.
Knoll MD, Wonodi C. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021;397(10269):72-4.
Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021;n699.
Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021. MMWR Morb Mortal Wkly Rep 2021;70(9):329-32.
Mahase E. Covid-19: Novavax vaccine efficacy is 86 % against UK variant and 60 % against South African variant. BMJ 2021;n296.
Ministerio de Salud y protección social. Plan nacional de vacunación contra covid- 19. https://www.valoraanalitik.com/wp-content/uploads/2020/06/pnv-contra-covid-19.pdf (Fecha de consulta: 10 de abril, 2021)
Alvarado Socarras JL, Vesga Varela AL, Quintero Lesmes DC, Fama Pereira MM, Serrano Diaz NC, Vasco M, et al. Perception of COVID-19 Vaccination Amongst Physicians in Colombia. Vaccines 2021;9(3):287.
INS reporta nueva actualización genómica en Colombia. Instituto Nacional de Salud. https://www.ins.gov.co/BibliotecaDigital/boletin-prensa-ins-12-03-2021-actualizacion-genomica-en-colombia.pdf#search=vigilancia%20genomica (Fecha de consulta: 2 de abril, 2021)
Pfizer- BioNTech announce positive topline results of pivotal Covid-19 Vaccine study in adolescents. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal (Fecha de consulta: 2 de abril, 2021)